Tag: CLI

New update on Phase III clinical trials of REX-001 cell-based therapy...

Rexgenero, a regenerative medicine company working to develop cell-based therapies to treat critical limb ischaemia (CLI), has presented an update on its two Phase...

VIVA 2018 focuses on the critical issues in vascular medicine

 In the arterial space, VIVA 2018 focused on the fact that there is an increasing awareness of limb threatening ischaemia coupled with an increase...

Lutonix BTK IDE: First Level 1 evidence of positive safety and...

 Patrick Geraghty (St Louis, USA) presented new datapoints from the six-month outcomes of the Lutonix BTK IDE trial at the 2018 VEITHsymposium (13–17 November,...

Lutonix 014 DCB gathers first randomised evidence of positive safety and...

Six-month outcomes of the Lutonix BTK IDE trial, a multicentre randomised controlled trial using the Lutonix 014 drug-coated balloon (DCB; BD), has demonstrated that...

Peripheral arterial disease patients at increased risk for high opioid use

Patients with peripheral arterial disease (PAD) are found to have an increased risk for high opioid use. Nathan Itoga and colleagues from the University...

First-ever CE mark of a bioresorbable scaffold for below-the-knee PAD

Reva Medical, a company developing bioresorbable polymer technologies for vascular applications, has announced that its Motiv bioresorbable scaffold is the first drug-eluting bioresorbable scaffold...

Intraoperative oxygen monitoring predicts wound healing in critical limb ischaemia patients...

Preliminary findings from an initial study with 25 patients have shown that measuring the changes in oxygen concentration at baseline, during, and after endovascular...

LimFlow completes enrolment in US feasibility study

LimFlow has announced completion of enrolment of the original 10-patient cohort in the US feasibility study of the LimFlow percutaneous deep vein arterialisation system....

LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...

Medtronic added to its body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical outcomes...

New analysis suggests peripheral artery disease affects 42–60 million Chinese citizens

A new analysis published by The Sage Group has concluded that 42–60 million Chinese citizens are afflicted by peripheral artery disease (PAD), with 5.6–6.3...

Intact Vascular announces enrolment of first European patient in TOBA II...

Intact Vascular’s TOBA II BTK (Tack optimized balloon angioplasty II below the knee) clinical trial has commenced enrolment in Europe, with the first patient treated by Marianne Brodmann and Peter Reif...

First patient treated in LimFlow US feasibility study as international post-market...

LimFlow SA has announced enrolment of the first patient in the US feasibility study of the LimFlow percutaneous deep vein arterialisation (pDVA) system, a novel,...

FDA approves six-month primary endpoint for Tack endovascular system in below-the-knee...

The US Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint in Intact Vascular’s TOBA II...

Endovascular therapy for critical limb ischaemia: When is enough, enough?

We need to stop doing endovascular procedures for critical limb ischaemia patients when no measurable benefit is being seen and when the adverse event rate is...

Surgery-first approach for critical limb ischaemia offers faster wound healing rate...

A surgical-first strategy appears to be superior to endovascular treatment for critical limb ischaemia revascularisation, exhibiting improved wound healing rate and overall healing time,...

Autologous bone marrow cell injection reduces one-year amputation rate for Rutherford...

Fifty-two-week outcomes of the MOBILE trial indicate a “significant reduction in major amputations” among Rutherford 4 and non-diabetic Rutherford 5 critical limb ischaemia patients...

Cardiovascular Systems releases 30-day results from LIBERTY 360° study

Cardiovascular Systems has released procedural and 30-day results from its LIBERTY 360° study in a late-breaking presentation at the 2016 Amputation Prevention Symposium (AMP;...